Company: RGNT
Filing Date: 2025-05-19
Form Type: F-1/A
Source: 0001213900-25-045479
Chunk: 129

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-05-19
Form: F-1/A
Chunk 129
---
 in the table below.

The patent portfolio of the
Company includes granted patents that cover the products currently in development and additional families of patents that may provide
supplementary protection for those products and further products.

<div align='center'>76</div>

Patents

As of April 7, 2025, our exclusively owned patent portfolio includes thirty-four (34) issued patents, of which eight (8) are U.S. patents and twenty-six (26) are foreign patents, with eighteen (18) of the twenty-six (26) foreign patents being nationally validated in certain European extension/validation states). In addition, one U.S. patent application and three patent applications are pending. The claims of the owned patents and patent applications below are directed toward various aspects of our family of products, methods of their manufacturing, delivery device and research programs.

| Effective     
 Filing Date   |     | Patent        
 No.           |     | Title                                                                                                             |     | Country                       |     | Product         |     | Type              
 of                
 patent protection |     | Expiry date1   |
| Dec. 15, 2004 |     | US 8,007,774  |     | Matrix composed of a                                                                                              
 naturally-occurring protein backbone cross linked by a synthetic polymer and methods of generating and using same |     | USA                           |     | Gelrin          |     | Utility patent    |     | Dec. 31, 20252 |
| Dec. 15, 2004 |     | US 9,120,872  |     | Matrix composed of a                                                                                              
 naturally-occurring protein backbone cross linked by a synthetic polymer and methods of generating and using same |     | USA                           |     | Gelrin          |     | Utility patent    |     | Dec. 31, 20252 |
| Dec. 15, 2004 |     | US 8,858,925  |     | Pegylated fibrinogen                                                                                              
 precursor molecule                                                                                                |     | USA                           |     | Gelrin          |     | Utility patent    |     | Jun. 28, 20252 |
| Jun. 21, 2007 |     | EP 1870115    |     | Immediate release compositions                                                                                    
 for treating tissue damages                                                                                       |     | Germany, Spain, France,       
 United Kingdom, Italy         |     | Gelrin          |     | Utility patent    |     | Jun. 6, 2027   |
| Apr.